Ozempic vs Wegovy
By Dr Chad Okay5 min read

Ozempic and Wegovy are both semaglutide. Same molecule. Different brand, different dose ladder, different licensed indication. Ozempic is licensed for type 2 diabetes (up to 2 mg weekly). Wegovy is licensed for weight management (up to 2.4 mg weekly). The pens look similar but are not interchangeable. If you have diabetes, Ozempic. If your reason is weight loss alone in the UK, Wegovy.
If you've been confused by Ozempic vs Wegovy, you're in good company. They're the same drug at different doses with different labels. Here's a clean breakdown of what differs and what doesn't.
What's identical
- Active ingredient: semaglutide.
- Manufacturer: Novo Nordisk.
- Mechanism: GLP-1 receptor agonist. Slows gastric emptying, reduces appetite, lowers blood sugar.
- Side effect profile: nausea, constipation, reflux, fatigue.
- Pen design: very similar; both are weekly self-injection pens.
- Storage: refrigerated unopened, room temperature once in use.
What differs
| Detail | Ozempic | Wegovy |
|---|---|---|
| Licensed for | Type 2 diabetes; CV risk reduction in T2D | Weight management (licence: BMI ≥30, or ≥27 with a weight-related condition) |
| Maximum dose | 2 mg weekly | 2.4 mg weekly |
| Dose ladder steps | 0.25 → 0.5 → 1 → 2 mg | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg |
| Time to maintenance | 16 weeks | 16-20 weeks |
| Average weight loss at 12 months | ~6-7% (1-2 mg) | 15% (2.4 mg) |
| NHS access | Routine for T2D not controlled on metformin | Through specialist weight-management services, for a maximum of 2 years (NICE TA875) |
| UK monthly cost (private) | £200-300 | £200-300 |
Why two brands for the same drug?
Regulatory licensing. To get approved for weight loss, the drug needed dedicated trials in a non-diabetic obese population (the STEP trials). Once those completed, Novo Nordisk launched the higher-dose version under a separate brand. This gives clearer prescribing pathways, separate pricing in some markets, and avoids confusion when prescribers and the people they prescribe for are talking about diabetes vs weight management goals.
Which one fits which situation
- Type 2 diabetes (with or without obesity): Ozempic is the standard NHS pathway. Wegovy might be considered later if weight is the primary issue.
- Obesity without diabetes (UK): Wegovy is the licensed option. NHS access is restricted to Tier 3 services; most UK users currently pay privately.
- Pre-diabetes plus obesity: NICE recommends Wegovy via specialist services. Some private clinics will prescribe directly.
- If supply of one is unstable: switching between Ozempic and Wegovy is sometimes possible with prescriber support, since the drug is the same. Dose conversion isn't 1:1 because the dose ladders are different.
Side effects compared
- Nausea: more common at the higher Wegovy dose (~44% on 2.4 mg, STEP 1-3 pooled, Wharton 2022) than on Ozempic (~15-19% across the SUSTAIN programme, Aroda 2023). Typically mild to moderate and eases after the first weeks at each dose step.
- Constipation: Wegovy 2.4 mg ~24% (STEP 1-3 pooled, Wharton 2022), Ozempic 1 mg ~6% (SUSTAIN/PIONEER pooled, Aroda 2023).
- Diarrhoea: Wegovy 2.4 mg ~30% (Wharton 2022), Ozempic ~10-13% (Aroda 2023).
- Vomiting: not rare. About 24% on Wegovy 2.4 mg versus 6% on placebo in the pooled STEP trials (Wharton 2022), and around 7% across the SUSTAIN trials. It clusters during dose escalation.
- Pancreatitis, gallstones, severe gastroparesis: uncommon on both, well-recognised. Severe, persistent abdominal pain needs same-day medical assessment, not a wait-and-see approach (see below).
- Hair shedding: listed in the Wegovy prescribing information and reported on both. It is thought to track rapid weight loss itself rather than the drug, and usually settles as weight stabilises.
If something feels wrong
This article is about comfort and everyday patterns, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.
What you can't get on either
- Tirzepatide (Mounjaro/Zepbound), different molecule, different drug class (dual GLP-1 + GIP), produces more weight loss in head-to-head trials.
- Compounded semaglutide from US-style mid-tier pharmacies, quality, sterility, and dose accuracy are all unverifiable. Avoid.
- Daily injection equivalents (Saxenda, Victoza), those are liraglutide, an older shorter-acting GLP-1.
- Oral semaglutide: Rybelsus (3, 7, 14 mg) is licensed for type 2 diabetes only. The Wegovy pill, once-daily oral semaglutide 25 mg, was FDA-approved for chronic weight management on 22 December 2025 (mean weight loss 16.6% among participants who stayed on treatment in OASIS 4); UK availability lags.
Common questions
The drug is the same, the dose ladders aren't. You can switch under prescriber supervision but not just swap pens. The 2 mg Ozempic dose is closer to the 2.4 mg Wegovy dose than to the lower Wegovy doses, so a direct conversion isn't precise.
Sources
- 1Ozempic 1 mg SmPC (semaglutide): T2D indication, dose ladder to 2 mg, GI adverse-reaction frequencieselectronic medicines compendium (emc), Novo Nordisk
- 2Wegovy 2.4 mg SmPC (semaglutide): weight-management indication, 16-week dose escalation, nausea/constipation/diarrhoea frequencieselectronic medicines compendium (emc), Novo Nordisk
- 3STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity, Wilding et al, 2021 (14.9% at 68 weeks)NEJM (PubMed)
- 4SUSTAIN FORTE: semaglutide 2.0 mg vs 1.0 mg in type 2 diabetes, Frias et al, 2021 (-6.9 kg vs -6.0 kg at week 40)The Lancet Diabetes & Endocrinology (PubMed)
- 5SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, Aronne et al, 2025 (-20.2% vs -13.7%)NEJM (PubMed)
- 6NICE TA875: Semaglutide for managing overweight and obesity, Recommendations (BMI >=35 + comorbidity, specialist service, max 2 years)NICE
- 7OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity, 2025 (basis of the FDA approval of oral Wegovy, 22 Dec 2025)NEJM (PubMed)
- 8Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg (STEP 1-3 pooled), Wharton et al, 2022: nausea 43.9%, diarrhoea 29.7%, vomiting 24.5%, constipation 24.2%Diabetes, Obesity and Metabolism (PubMed)
- 9Safety and tolerability of semaglutide across the SUSTAIN and PIONEER programmes, Aroda et al, 2023: nausea 15.4-19.1%, diarrhoea 10.1-12.6%, vomiting 6.6-7.5%Diabetes, Obesity and Metabolism (PubMed)
- 10Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
Words in this piece




